Replimune Group (NASDAQ:REPL) Stock Jumps 5.1% – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares were up 5.1% on Tuesday. The stock traded as high as $13.26 and last traded at $13.1970. 1,085,693 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 4,544,294 shares. The stock had previously closed at $12.56.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, August 26th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a research note on Friday, August 7th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Finally, Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Replimune Group Stock Up 4.2%

The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The firm has a market cap of $1.23 billion, a P/E ratio of -4.19 and a beta of 0.94. The stock’s fifty day moving average is $13.04 and its two-hundred day moving average is $9.21.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, research analysts anticipate that Replimune Group, Inc. will post -2.81 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Emily Hill sold 9,256 shares of Replimune Group stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the sale, the chief financial officer owned 215,852 shares in the company, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at $9,184,718.47. The trade was a 5.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock worth $1,038,364 over the last three months. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently bought and sold shares of REPL. BlackRock Inc. bought a new position in shares of Replimune Group in the 2nd quarter worth $99,171,000. Montanova Capital LLC lifted its holdings in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after acquiring an additional 168,000 shares during the last quarter. Erste Asset Management GmbH grew its position in Replimune Group by 30.1% in the fourth quarter. Erste Asset Management GmbH now owns 2,120,000 shares of the company’s stock worth $20,619,000 after acquiring an additional 490,000 shares in the last quarter. Commodore Capital LP bought a new position in Replimune Group in the fourth quarter valued at $13,851,000. Finally, Opaleye Management Inc. purchased a new stake in Replimune Group during the second quarter valued at about $15,332,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.